Pachter, Jonathan A.

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M., Hawkins, W. G., Shapiro, I. M., Weaver, D. T., et al. (2016) · Nature Medicine

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 1,060

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R. C., von Kriegsheim, A., Gómez-Cuadrado, L., Canel, M., Muir, M., Ring, J. E., et al. (2015) · Cell

Cancer Immunotherapy and BiomarkersCell Adhesion Molecules Research

Cited by 407

A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK

Feng, X., Arang, N., Rigiracciolo, D. C., Lee, J. S., Yeerna, H., Wang, Z., Lubrano, S., Kishore, A., Pachter, J. A., König, G. M., et al. (2019) · Cancer Cell

Hippo pathway signaling and YAP/TAZOcular Oncology and Treatments

Cited by 237

Expression and Characterization of Recombinant Type 2 3α-Hydroxysteroid Dehydrogenase (HSD) from Human Prostate: Demonstration of Bifunctional 3α/17β-HSD Activity and Cellular Distribution

Lin, H.-K., Jez, J. M., Schlegel, B. P., Peehl, D. M., Pachter, J. A., & Penning, T. M. (1997) · Molecular Endocrinology

Prostate Cancer Treatment and ResearchAldose Reductase and Taurine

Cited by 194

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

Diaz Osterman, C. J., Ozmadenci, D., Kleinschmidt, E. G., Taylor, K. N., Barrie, A. M., Jiang, S., Bean, L. M., Sulzmaier, F. J., Jean, C., Tancioni, I., et al. (2019) · eLife

Ovarian cancer diagnosis and treatmentCancer Cells and Metastasis

Cited by 145

Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion

Jiang, H., Liu, X., Knolhoff, B. L., Hegde, S., Lee, K. B., Jiang, H., Fields, R. C., Pachter, J. A., Lim, K.-H., & DeNardo, D. G. (2020) · Gut

Pancreatic and Hepatic Oncology ResearchTGF-β signaling in diseases

Cited by 130

RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).

Reuss, J. E., Gandhi, S. G., Spigel, D. R., Janne, P. A., Paz-Ares, L. G., Gadgeel, S. M., Patel, J. D., Passiglia, F., Spira, A. I., Edelman, M. J., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 7

Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response

Stewart, A. R., Pickard, L., Paranjape, E., Perez, V. S., Chowdhury, S., Lustgarten, S., Coma, S., Pachter, J. A., Carey, M. S., DiMattia, G., et al. (2022) · Cancer Research

Ovarian cancer diagnosis and treatmentMelanoma and MAPK Pathways

Cited by 1